A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules

Burak Kürsad Günhan, Sebastian Weber, Tim Friede

Phase I dose-escalation trials must be guided by a safety model in order to avoid exposing patients to unacceptably high risk of toxicities. Traditionally, these trials are based o…